Sample characteristics
| N (%) | |
| Companies | 42 |
| Size | |
| Large | 17 (40) |
| Non-large | 25 (60) |
| Headquarter location | |
| US | 26 (62) |
| Non-US | 16 (38) |
| Products | 62 |
| Type | |
| Drugs | 40 (65) |
| Biologics | 22 (35) |
| FDA approval year | |
| 2016 | 16 (26) |
| 2017 | 46 (74) |
| Trials | 1017 |
| Trials conducted in patients | 391 (38) |
| FDAAA applicable trials | 236 (23) |
| Median number of trials supporting each product approval (IQR) | 13 (8–21) |
| Median number of trials in patients for approved indication supporting each product approval (IQR) | 5 (3–8) |
| Median number of FDAAA applicable trials supporting each product approval (IQR) | 3 (2–5) |
FDA, Food and Drug Administration; FDAAA, FDA Amendments Act.